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1. Abstract 
Background: Muscle pain is a common condition that relates to various diseases and is induced by muscle 
overuse. Muscle overuse induces an increase of uric acid which induces the Nucleotide-binding 
oligomerization domain-like receptor containing pyrin domain (NLRP) 3 inflammasome activation which 
subsequently induces secretion of potent pro-inflammatory cytokines such as interleukin-1β (IL-1β). The aim 
of this study was to investigate the involvement of inflammasome activation via elevation of uric acid level 
on nociception in mouse model of muscle pain. 
Materials and methods: The triceps surae muscle of the right hind leg of BALB/c mice were stimulated 
electrically at 10 Hz with a 10-V amplitude and a 100-µs pulse width for 30 minutes using wire electrodes to 
induce excessive muscle contraction. The left hind leg muscles were not stimulated. The pressure pain 
thresholds (PPTs), the levels of uric acid, NLRP3, caspase-1 activity, IL-1β and number of macrophages 
were investigated. Furthermore, the effects of the xanthine oxidase inhibitors, Brilliant Blue G, caspase-1 
inhibitor and clodronate liposome on pain were investigated. 
Results: In stimulated muscles, PPTs decreased, and the levels of uric acid, NLRP3, caspase-1 activity, IL-
1β and number of macrophages increased compared with that in non-stimulated muscles. The administration 
of drugs which were described above attenuated hyperalgesia caused by excessive muscle contraction. 
Conclusions: IL-1β secretion and NLRP3 inflammasome activation in macrophages due to elevation of uric 
acid level produce mechanical hyperalgesia. 
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2. Introduction 
Musculoskeletal disorders are the most prevalent causes of chronic health problems, disabilities, 
and health care utilization.1,2 Among these health conditions, muscle pain is a common condition3 that relates 
to various pathologies such as neck and shoulder pain,4 non-specific low back pain,5 and myofascial pain 
syndrome (MPS).6-9 Hanvold TN et al. reported that sustained trapezius muscle activity increases the rate of 
neck and shoulder pain.4 Neck and shoulder pain occurs in more than 30% of the working population,10 and 
is a risk factor for long-term absenteeism.11,12 van Dieën JH et al. reviewed relationship between trunk 
muscle activity and low back pain.5 Lower back pain has a lifetime prevalence of as high as 84% and causes 
disabilities of 11–12% in the general population.13 MPS is a disorder of musculoskeletal origin which is 
associated with local pain and muscle stiffness, characterized by the presence of hyperirritable palpable 
nodules in the skeletal muscle fibers (so-called trigger points).8 Although the etiology of MPS remains 
controversial, it is reported that sustained shortening and contracture of sarcomere, which is the basic unit of 
muscle tissue, produces trigger points.7 MPS is very common in the general population, and its incidence 
may be as high as 54% in women and 45% in men.8 Furthermore, MPS is a primary source of pain in 
between 30% to 85% of patients presenting at a primary care setting or pain clinic.7,14,15 Although numerous 
treatment methods, such as pharmacological treatments using non-steroidal anti-inflammatory drug, 
physiotherapy and dry needling, have been developed to reduce the pain, no single successful strategy is 
available as the underlying pathogenic mechanisms have not been fully determined.6,7,9 Muscle overuse, 
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especially with eccentric contraction, induces muscle pain during exercise due to an increase of adenosine 
triphosphate (ATP) and lower pH.3,16,17 Muscle fiber destruction due to muscle overuse induces the release of 
ATP which activates the specific receptors (so-called nociceptors).3,17 Sustained muscle contraction and 
chronic muscle ischemia induce a decrease in pH in affected tissues.3,17  
Inflammatory responses to exercise-induced muscle damage also produce muscle pain.16 
Neutrophils invade skeletal muscle within several hours and remain present up to 24 h after exercise.16 
Macrophages are present in muscle from 24 h to 14 days after exercise.16 After invading the muscle, 
neutrophils and macrophages produce proinflammatory cytokines such as interleukin (IL) -1β, tumor 
necrosis factor (TNF) -α after exercise-induced muscle damage.16 In a muscle pain model, IL -18 was 
secreted from neutrophils.18 
Muscle overuse induces an increase of uric acid level, which is released from damaged cells.19-24 
Uric acid is the final product of dietary and endogenous purine metabolism. At the most downstream, 
xanthine oxidase (XO) converts hypoxanthine to xanthine and subsequently xanthine to uric acid.25 The 
purine metabolism system is extremely active during high-intensity exercise and muscle ischemic 
conditions.20 Uric acid circulates as the deprotonated urate anion under physiologic conditions and combines 
with sodium ions to form monosodium urate (MSU).26 When the uric acid level in serum reaches the 
solubility limit, MSU crystal formation begin.26 MSU crystal induces the inflammasome activation.27,28  
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Inflammasomes are a group of protein complexes which were the first reported in 2002.27,29 
Inflammasome complexes are composed of several proteins, including Nucleotide-binding oligomerization 
domain-like receptor (NLR) containing pyrin domain (NLRP) 1, NLRP3, NLRP6, NLR containing caspase 
activation and recruitment domain 4 (NLRC4) and absent in melanoma 2 (AIM2).27 Inflammasomes 
recognize a diverse set of inflammation-inducing stimuli that include pathogen-associated molecular patterns 
which are predominantly found in microbes, and damage-associated molecular patterns which are released as 
a result of cellular damages caused by microbial or non-microbial insults.27 After recognition of the stimuli, 
inflammasomes form assembly and result in direct activation of caspase-1, which subsequently induces 
secretion of potent pro-inflammatory cytokines such as interleukin-1β (IL-1β) and IL-18 and a form of cell 
death called pyroptosis.27 The inflammasome activation is known to be involved in various pathologies such 
as microbial infection, autoinflammatory diseases, arteriosclerosis and diabetes.27 NLRP3 is activated 
aberrant formation of crystals from endogenous molecules such as MSU.27,28 Phagocytosis of MSU crystals 
by macrophages and recognition by P2 purinergic receptors induces the NLRP3 inflammasome activation 
and releases IL-1β.21,27,28  
IL-1β is a pro-inflammatory cytokine which is released from various cells including keratinocytes, 
synoviocytes and macrophages.29-30 Although IL-1β has numerous important functions in the normal 
condition, overproduction of IL-1β is implicated in various diseases such as rheumatoid arthritis and 
osteoarthiritis.33,34 It has been reported that IL-1β is involved in pain.35,36 Reeve AJ et al. reported that 
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intrathecally injection of IL-1β induces hyperalgesia.35 Zelenka M et al. reported that injection of IL-1β into 
the peripheral nerve produces hyperplasia.36 IL-1β is involved in pain by causing the release and activation 
of nociceptive molecules such as Prostaglandins and Substance P.37,38 Additionally, IL-1β occurs directly on 
nociceptors and modulates neuronal excitability in sensory neurons.39  
Involvement of inflammasome-mediated processes in numerous painful diseases including gout,28 
pseudogout,40 and osteoarthritis41 has been reported. However, few reports have described the relationship 
between inflammasome and muscle pain. The aim of the present study was to investigate the roles of IL-1β 
secretion due to the inflammasome activation via elevation of local uric acid level of muscle tissue in 
mechanical hyperalgesia induced by repeated, excessive muscle contractions in mouse.  
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3. Materials and methods 
3.1 Experimental animals 
Protocol for this experiment was approved by the Animal Research Committee of Tohoku 
University (approval number: 2016MdA-240). Male, 5–7-week-old BALB/c mice (body weight 20–23 
g), were obtained from Japan CLEA (Tokyo, Japan). The mice were housed under a 12: 12-h light–dark 
cycle at 23 ± 1°C. 
 
3.2 Repeated electrical stimulation of triceps surae muscles 
Repeated electrical stimulation was used to induce excessive muscle contraction. After each 
mouse was anesthetized with an intraperitoneal injection of medetomidine (ZENOAQ, Fukushima, 
Japan, 0.3 mg/kg), midazolam (SANDZ, Tokyo, Japan, 4.0 mg/kg), and butorphanol (Meiji Seika 
Pharma Co, Tokyo, Japan, 5.0 mg/kg), 2 wire electrodes (Single-Stranded Stainless-Steel Wire, A-M 
System, Sequim, WA, USA) were transcutaneously applied into the triceps surae muscle of the right 
hind leg. Wire electrodes were placed on the proximal and distal ends of the muscle. After placing the 
wire electrodes, electrical stimulation of the muscle was performed at 10 Hz with a 10-V amplitude and 
a 100-µs pulse width for 30 minutes using a STG4004 multichannel system (MCS GmbH, Reutlingen, 
Germany), as previously described.18,42 During electrical stimulation for 30 minutes, the right hind leg 
was immobilized with the ankle joint in maximum dorsal flexion so that the triceps surae muscle was 
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fully extended to induce isometric contraction (Figure 1). The electrical stimulation was performed for 7 
days per week. The wire electrodes were also applied to the contralateral triceps surae muscle without 
electrical stimulation or immobilization. 
 
3.3 Assessment of mechanical nociceptive thresholds 
The pressure pain threshold (PPT) was assessed using the Randall–Selitto test (MK-201D 
PRESSURE ANALGESY-METER, Muromachi Kikai Co., Tokyo, Japan).43 This test employed a cone-
shaped plastic tip (tip diameter: 2.6 mm) attached to a scale with a display (Figure 2a). A linearly 
increasing pressure (10 mm Hg/s) was applied to the lateral surface of the triceps surae muscle. Mice 
were loosely wrapped in a towel to calm them down and were treated gently during the experiment. The 
PPT was defined as the amount of pressure (mm Hg) required to elicit pain-related behaviors such as 
vocalization, struggling, and leg withdrawal (Figure 2b).18,42 The cut-off value of the PPT was 300 mm 
Hg.44 PPT assessment of both hind legs was performed every day for 13 days after initiation of the 
electrical stimulation. All experiments investigating mechanical hyperalgesia were performed in the 
morning as circadian rhythm affects pain sensitivity. To avoid biases, assessment of the PPT data was 
performed by a blinded investigator. 
 
3.4 Local effect of MSU on hyperalgesia 
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To confirm the local effects of MSU, recrystallized MSU (Monosodium Urate, #133-13432; 
Wako Pure Chemicals Industries, Osaka, Japan) dissolved in saline was administrated to the right triceps 
surae muscle (MSU group) as previously described.45 At the same time, saline alone was administrated 
to the contralateral triceps surae muscle (Saline group). The volume of injected solution was 50 μl in 
each group. At 0, 1, 2, and 4 days’ post-injection, PPTs were assessed as described above and the triceps 
surae muscles were obtained for measurement of NLRP3 and IL-1β levels by enzyme-linked 
immunosorbent assay (ELISA). 
 
3.5 Tissue preparation 
On day 7 after the initiation of electrical stimulation, mice were sacrificed by cervical 
dislocation and the triceps surae muscles were obtained. Specimens for ELISAs and fluorometric assays 
were frozen in liquid nitrogen and stored at –80ºC. For immunohistochemical staining, the specimens 
were immersed in 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4) overnight at 4ºC. After 
dehydration through a graded series of ethanol solutions, the specimens were embedded in paraffin. The 
embedded tissues were cut into 5-μm axial sections. 
 
3.6 ELISA experiments 
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For the measurement of IL-1β levels, tissue samples were disrupted and homogenized using 
lysis buffer composed of bovine serum albumin (BSA; 100μg/ml, A4503, Sigma–Aldrich, St. Louis, 
MO, USA), Triton X-100 (0.1%, Wako Pure Chemicals Industries), 1 M HEPES (1%, 533-08083, Wako 
Pure Chemicals Industries), protease inhibitor (1%, P8340, Sigma–Aldrich), and distilled water (DW). 
After homogenization, samples were centrifuged for 10 minutes at 9,730 × g and 4ºC, and the 
supernatant was stored at -80ºC. IL-1β expression levels were analyzed with a Bio-Plex Multiplex 
Immunoassay System (Bio-Rad, Hercules, CA, USA) and a Bio-Plex Pro Mouse Cytokine 23-plex 
Assay (Bio-Rad), according to the manufacturer’s instructions. For the measurement of NLRP3 levels 
was performed using Mouse NALP3 / NLRP3 ELISA Kit (LS-F17336, LifeSpan Biosciences Inc., 
Seattle, WA, USA). Tissue samples were disrupted and homogenized using PBS. After homogenization, 
the samples were repeatedly frozen (-20ºC) and thawed (room temperature) three times to lyse the cells. 
After that, samples were centrifuged for 5 minutes at 5,000 × g and 4ºC, and the supernatant was used 
for the assay according to the manufacturer’s instructions. 
 
3.7 Fluorometric assay experiments 
For the measurement of uric acid level and caspase-1 activity was performed using Uric Acid 
Colorimetric / Fluorometric Assay Kit (K608-100, BioVision Inc., Milpitas, CA, USA) and Caspase 1 
Assay Kit (ab39412, Abcam plc), respectively. Tissue samples were disrupted and homogenized using 
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buffers contained in each kit. After homogenization, the samples were centrifuged for 5 minutes at 
12,000 rpm and 4ºC, and the supernatant was used for the assay according to the manufacturer’s 
instructions. Values of caspase-1 activity were normalized to controls which were not stimulated and 
administrated any drugs. 
 
3.8 Immunohistochemistry 
Tissue sections were deparaffinized and washed in PBS. Subsequently, they were incubated 
with solution consisting of Proteinase K (Takara Bio Inc. Shiga, Japan, 25μl), 0.5M 
ethylenediaminetetraacetic acid (EDTA, Invitrogen, Carlsbad, CA, USA, 0.5ml), 1M Tris-Cl (pH 8.0, 
2.5ml) and DW, 50ml) for 5 minutes at 37ºC to induce antigen retrieval. After washing in PBS, 
endogenous immunoglobulins were blocked by incubation with 10% normal goat serum (Nichirei 
Biosciences Inc., Tokyo, Japan) for 3 hours. The slides were washed again in PBS and incubated with a 
polyclonal rabbit anti-mouse NLRP3 antibody (NBP2-12446, Novus Biologicals, Littleton, CO, USA, 
dilution 1 : 25), a polyclonal rabbit anti-mouse caspase-1 antibody (ab1872, Abcam plc, Cambridge, 
UK, dilution 1 : 25), a polyclonal rabbit anti-mouse IL-1β antibody (ab9722, Abcam plc, concentration 
of 10μg/ml) and a monoclonal rat anti-mouse Cluster of Differentiation (CD) 68 antibody (ab53444, 
Abcam plc, concentration of 10μg/ml) in PBS overnight at 4ºC, and then rinsed in PBS. Subsequently, 
the slides were incubated for 1 hour in PBS with an Alexa Fluor 488-conjugated goat anti-rabbit IgG 
13 
 
(A-11034, Life Technologies, Carlsbad, CA, USA, dilution 1 : 750) for NLRP3, caspase-1, IL-1β and an 
Alexa Fluor 555-cojugated goat anti-rat IgG (A-21434, Life Technologies, dilution 1 : 750) for CD68 at 
room temperature, after which they were rinsed in PBS. Finally, the slides were incubated with 4,6-
diamidino-2-phenylindole (Sigma–Aldrich, dilution 1 : 500) for 10 minutes at 25°C for nuclear staining. 
Images were captured with a fluorescence microscope (BZ-9000 BIOREVO, KEYENCE, Osaka, 
Japan). The images were analyzed using Adobe Photoshop (Adobe System Inc., San Jose, CA, USA). At 
least three images in each slide were captured at magnification 200 and the number of CD-68-positive 
cells (macrophages) was counted. The number was presented to cells/view. The evaluation was 
performed by two blinded investigators to avoid biases. Two animals were used for 
immunohistochemistry, and two slides/animal were analyzed. After confirming reproducibility, 
representative images were presented. 
 
3.9 Assessment of the effect of drug administration 
To test the effects of hyperalgesia, IL-1β secretion, inflammasome activation and elevation of 
uric acid level, several agents were administrated to mice intraperitoneally during repeated electrical 
stimulation of the triceps surae muscles. Allopurinol (A8003, Sigma–Aldrich, 200mg/kg/72hours),46 
Febuxostat (F0847, Tokyo Chemical Industry Co., Ltd., Tokyo, Japan, 5mg/kg/24hours),47 Brilliant Blue 
G pure (BBG, B0770, Sigma–Aldrich, 45.5mg/48hours),48 Caspase-1 inhibitor Z-WEHD-FMK 
14 
 
(FMK002, R&D Systems, Inc., Minneapolis, MN, USA, 1mg/kg/24hours),49 Liposomal clodronate 
(XYGIEIA BIOSCIENCE, Osaka, Japan, 200μl/body/48hours)50 were used. Allopurinol and Febuxostat 
are XO inhibitor which reduce uric acid formation by inhibiting of XO which converts hypoxanthine to 
xanthine and uric acid.46,47 Besides these, there are other types of uric acid lowering agents; drugs that 
normalize renal urate excretion by acting on the renal tubules, including probenecid, benzbromarone; 
drugs that catalyze the conversion of urate to the more water soluble and readily excretable allantoin, 
such as pegloticase and rasburicase.51 Among these, XO inhibitor is most frequently used as a first-line 
drug.51 Additionally, if these drugs are used in this study, it is not necessary to consider uric acid 
excretion mechanism in mouse kidney. For these reasons, XO inhibitor was used in this study. To the 
best of our knowledge, there is no drug which inhibit crystallization of uric acid in muscle tissue. BBG 
is a selective P2X7 receptor antagonist that attenuates NLRP3 inflammasome activation.48 Caspase-1 
inhibitor Z-WEHD-FMK is a caspase-1 inhibitor used blockade of caspase-1 activity and subsequently 
production of IL-1β.49 Clodronate liposome induces macrophage depletion by killing these cells as a 
result of accumulation and irreversible metabolic damage.50 Control animals received an equivalent 
volume of 0.9% saline (saline group). The PPTs were assessed by performing the Randall–Selitto test on 
day 7. Measurement of uric acid, NLRP3, IL-1β levels and caspase activity was performed as 
described above. 
 
15 
 
3.10 Assessment of hyperalgesia on IL-K.O. mouse 
To test the effects of deficient of IL-1β secretion on hyperalgesia, IL-1 K.O. mice were used. 
Repeated electrical stimulation was performed on IL-1 K.O. mice as described above and the PPTs were 
assessed by performing the Randall–Selitto test on day 7. 
 
3.11 Statistical analysis 
Statistical analyses were performed using SPSS Statistics 24 (IBM, Armonk, NY, USA). 
Analysis of PPT time-course data was performed by 2-way analysis of variance (ANOVA) with repeated 
measures with Tukey’s post-hoc multiple-comparison test. To compare data from more than three 
groups from a single day (PPTs, ELISA and fluorometric assay), 1-way ANOVA with Tukey’s post-hoc, 
multiple-comparison test was used for the analysis. NLRP3 and IL-1β data between the two groups were 
analyzed using the Wilcoxon signed-rank test. Other data between two groups were analyzed with the 
paired t test. Data were expressed as the mean ± standard error of the mean. A P value of < 0.05 was 
considered to represent statistical significance. 
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4. Results 
4.1 MSU induced mechanical hyperalgesia and inflammasome activation 
The PPTs of the MSU group significantly decreased from 1 day after administration compared with 
that before administration. It continued at least 4 days after administration. In the saline group, no significant 
changes were observed during between 1 and 4 days after administration compared with that before 
administration. Significant differences were observed between the MSU group and the saline group between 
1 to 4 days after administration (Figure 3a). On the 2 and 4 days after administration, induction of NLRP3 
and IL-1β in the MSU group significantly increased compared with that in saline group, as determined by 
ELISA (Figure 3b and c). 
 
4.2 Excessive contraction induced mechanical hyperalgesia, elevation of uric acid level, and 
inflammasome activation in muscles 
The PPTs of the stimulated muscles began to decrease on day 3, and significantly decreased during 
days 4 to 11 compared with that of non-stimulated contralateral muscle. Reduced PPTs in the stimulated 
muscles recovered after the electrical stimulation was completed, and no significant difference was observed 
in PPTs between stimulated and non-stimulated muscles after day 12. No significant changes were observed 
in the PPTs of non-stimulated muscles, during the experimental period compared with the values before 
electrical stimulation (Figure 4a). There was no evidence for secondary hyperalgesia during the experiments. 
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Induction of uric acid, NLRP3, caspase-1 activity and IL-1β in the stimulated muscles significantly increased 
compared with that in non-stimulated muscles (Figure 4b-e). 
 
4.3 Inflammasome activated in macrophages in stimulated muscle 
Immunohistochemical staining revealed an increased number of CD68-positive cells 
(macrophages) in stimulated muscles compared with that in the non-stimulated muscles. Most of these cells 
were also positive for NLRP3, caspase-1 and IL-1β (Figure 5a-r). The number of cells which were positive 
for both of IL-1β and CD68 in the stimulated muscles significantly increased compared with that in non-
stimulated muscles (Figure 5s). In the clodronate liposome group, the PPTs significantly increased and 
NLRP3, caspase-1 activity and IL-1β levels were significantly decreased compared with those in the saline 
group (Figure 5t-w). No significant differences were observed between the saline group and naïve group with 
electrical stimulation. 
 
4.4 XO inhibitors (allopurinol and febuxostat) attenuated hyperalgesia in excessively contracted 
muscles 
In both of the allopurinol and febuxostat group, the PPTs significantly increased and uric acid, 
NLRP3, caspase-1 activity and IL-1β levels significantly decreased compared with those in the saline group 
(Figure 6a-e). No significant differences were observed between the saline group and the naïve group with 
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electrical stimulation. The levels of uric acid and caspase-1 activity of the allopurinol and febuxostat group 
did not decrease to the same level as non-stimulated groups. 
 
4.5 BBG attenuated hyperalgesia in excessively contracted muscles 
The PPTs significantly increased and NLRP3, caspase-1 activity and IL-1β levels significantly 
decreased in the BBG group compared with those in the saline group (Figure 7a-d). No significant 
differences were observed between the saline group and the naïve group with electrical stimulation. The 
caspase-1 activity of the BBG group did not decrease to the same level as non-stimulated groups. 
 
4.6 Z-YVAD-FMK attenuated hyperalgesia in excessively contracted muscles 
In the Z-YVAD-FMK group, the PPTs significantly increased and caspase-1 activity and IL-1β 
levels significantly decreased compared with those in the saline group (Figure 8a-c). No significant 
differences were observed between the saline group and the naïve group with electrical stimulation. The 
caspase-1 activity of the Z-YVAD-FMK group did not decrease to the same level as non-stimulated groups. 
 
4.7 Excessive contracture did not induce mechanical hyperalgesia in IL-1 knock out mice 
In the IL-1 knock out mice, the PPTs of the stimulated muscles did not decrease compared with 
that of the non-stimulated contralateral muscle (Figure 9). 
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5. Discussion 
Data generated in the present study revealed the following: 1. The administration of MSU into the 
triceps surae muscles induced hyperalgesia and IL-1β elevation due to inflammasome activation, 2. 
Excessive muscle contraction by electrical stimulation induced mechanical hyperalgesia and elevation of uric 
acid elevation, inflammasome activation and IL-1β in the muscle, 3. The number of macrophages increased 
after electrical stimulation; NLRP3 inflammasome activation occurred in these macrophages, 4. 
Intraperitoneal administration of drugs including XO inhibitors, BBG and Z-YVAD-FMK attenuated 
hyperalgesia caused by excessive muscle contraction (Figure 10). 
MSU activates NLRP3 inflammasome.21,27,28 There are several previous reports that evaluate 
inflammasome activation by local administration of MSU.45,52,53 Ju TJ et al. and Yang G et al. reported MSU 
injection into the soles of mice hindlimb feet induced elevation of caspase-1 activity and IL-1β.45,52 Lee HE 
et al. reported elevation of NLRP3, caspase-1 activity and IL-1β by MSU injection into the subcutaneous 
tissue of back in mice.53 The data in this study corresponded well with these studies. 
It has been reported that muscle contraction in response to electrical stimulation induces 
mechanical hyperalgesia.42,54 This previously reported experimental protocol was followed in experiments 
using a similar pain model for the rat masseter muscle.42 Shinoda et al. reported that repeated muscle 
contraction (15 days) produced mechanical hyperalgesia 6-15 days following the initiation of contraction in 
the masseter muscle pain model in rats.42 In the present study, we made a new muscle pain model using the 
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triceps surae muscle of mouse because the mouse model is superior to past rat model in that cost is cheap and 
small and easy to handle. The results of the present study were similar to previous report which was 
conducted using rat model. Therefore, the present mouse model is suitable for investigation of triceps surae 
muscle pain induced by repeated excessive contraction. In order to induce muscle pain, mice were subjected 
to 7 days of contractions in this study. The duration of our experiments was shorter than that in previous 
studies as hyperalgesia of the muscle was observed at day 4. Although the wire electrodes were also inserted 
into the contralateral triceps surae muscle without electrical stimulation, hyperalgesia of the muscle was not 
observed. This finding demonstrates that the observed muscle hyperalgesia was caused by stimulation and 
not possible injury resulting from repetitive insertion of the wire electrodes. In the present study, the PPTs of 
the stimulated muscles significantly decreased compared with that of non-stimulated contralateral muscle at 
day 7. Because there were few variations in the numerical values, a significant difference was observed even 
with a small number of cases. The stimulated muscles which were harvested at day 7 is appropriate for 
investigation of muscle pain induced by repeated excessive contraction.  
It has been reported that muscle overuse induces an increase of uric acid level in human and 
mouse.19,20,22-24 Balsom et al. and Jówko et al. reported increase of uric acid level in serum after sprint in 
physical education students.19,20 Chatzinikolaou A et al. and Andersson H et al. reported that elevation of 
blood uric acid concentration and muscle soreness after exercise in team handball players and elite female 
soccer players, respectively.22,24 Retamoso LT et al. reported that an increase of uric acid levels in 
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gastrocnemius muscle of mouse after downhill running exercise.23 These reports supported our findings that 
an increase of uric acid in the stimulated muscles presented hyperalgesia. Although an increase of uric acid 
level and NLRP3 inflammasome activation was observed in stimulated muscle, our results did not present 
MSU crystals formation because polarizing microscope was not used. Although we tried to prove the 
existence of MSU crystals in muscle tissue using X-ray diffraction, we could not. According to previous 
studies, the solubility limit of uric acid is 405μmol/l in serum.26 In our results, the average of local uric acid 
concentration in stimulated muscle was almost 600μmol/l which is enough to crystal formation. Therefore, 
NLRP3 inflammasome activation in the stimulated muscles may have occurred. 
Although there are very few reports that have described the relationship between NLRP3 
inflammasome and muscle pain directly, several studies reported relationship between NLRP3 
inflammasome and fibromyalgia (FM) and chronic fatigue syndrome (CFS) which present muscle pain and 
fatigue.55-57 Bullón P et al. and Cordero MD et al. reported that overactivation of NLRP3 inflammasome 
occurs in blood mononuclear cells from patients with FM.55,56 Zhang ZT et al. reported that activation of 
NLRP3 inflammasome in the diencephalons, which is responsible for fatigue sensation, using mouse fatigue 
model with lipopolysaccharide (LPS) challenge combined with swim stress.57 These previous reports may 
support our finding that level of NLRP3, caspase-1 activity and IL-1β increased in the stimulated muscles. 
Although evaluation of NLRP3 inflammasome activity was performed only in peripheral muscle tissues 
22 
 
without additional testing of the central nervous system (CNS) in this study, it is quite possible that NLRP3 
inflammasome activation occurs in CNS considering the results of the study reported by Zhang ZT et al.57 
There are a few reports that NLRP3 inflammasome activation in skeletal muscle cell.58,59 Ding M 
et al. reported NLRP3 inflammasome activation in IFN-γ treated C2C12 cultured myotubes.58 McBride MJ et 
al. reported a contribution of NLRP3 inflammasome in sarcopenia.59 However, to the best of our knowledge, 
there is no previous report involvement of NLRP3 inflammasome in muscle pain. NLRP3 is mainly 
expressed by myeloid cells including monocytes and macrophages.21 In particular, it is well known that 
NLRP3 inflammasome activation induced by uric acid occurs in macrophage.27,28 Martinon F et al. and 
Gicquel T et al. reported inflammasome activation in monocyte cell line THP1 and human macrophages 
which were incubated with MSU crystals.21,28 These reports support our finding that NLRP3 inflammasome 
activation in macrophages which invaded into the stimulated muscle. There are previous reports that 
depleting macrophages by clodronate liposome suppresses NLRP3 inflammasome activation and release of 
IL-1β in several disease models such as lung tumor and alcoholic hepatosteatosis,60,61 but there was no report 
about muscle pain. Gregory NS et al. reported that clodronate liposome reduced hyperalgesia induced by 
injection of acid into muscle in combination with an electrical stimulation. They concluded that muscle 
fatigue decreases pH of muscle and activates acid-sensing ion channel 3 (ASIC3) on macrophages enhance 
hyperalgesia of muscle.62 This report suggests the association between previous reports that tissue low pH 
affects muscle pain and our results that macrophages are involved in muscle pain. 
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There are several previous reports that XO inhibitor inhibits NLRP3 inflammasome activation in 
various disease models.63,64 Aibibula Z et al. reported that febuxostat inhibited NLRP3 inflammasome 
activation in mouse model of metabolic syndrome.63 Similarly, Wan X et al. reported that allopurinol 
inhibited NLRP3 inflammasome activation in mouse model of non-alcoholic fatty liver disease.64 These 
reports support our findings that allopurinol and febuxostat inhibited NLRP3 inflammasome activation in the 
stimulated muscle. In the present study, although the uric acid levels in allopurinol group and febuxostat 
group did not decrease to the same level as non-stimulated muscle, the PPT recovered to the same level as 
non-stimulated muscle. There are previous studies which reported different mechanisms from uric acid-
mediated NLRP3 inflammasome activation as the cause of pain.65,66 Schmidt AP et al. reported that 
administration of allopurinol produced dose-dependent antinociceptive effects in chemical and thermal pain 
models.65 They concluded that allopurinol-induced anti-nociception may be related to adenosine 
accumulation which induces decreasing the release of painful substances including substance P and 
glutamate.65 Ives A et al. reported that XO-derived reactive oxygen species (ROS), but not uric acid, is the 
trigger for NLRP3 inflammasome activation and XO blockade results in impaired it.66 These mechanisms 
may explain the dissociation that occurred in the present study. There are several previous reports that XO 
inhibitor inhibits muscle damage in human. Sanchis-Gomar et al. and Gómez-Cabrera reported that 
allopurinol prevented the exercise-induced increase of the markers of skeletal muscle damage in soccer 
players and participants of bicycle race, respectively.67,68 They concluded that allopurinol prevented muscle 
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damage by inhibiting XO which is an important source of ROS generation during exercise.67,68 XO inhibitors 
may inhibit muscle damage and pain in multiple mechanisms, such as inhibition of ROS generation, uric acid 
production and inflammasome activation. 
BBG is a selective P2X7 receptor antagonist that attenuates NLRP3 inflammasome activation.48 
The P2X7 receptor is a trimeric ion channel gated by extracellular ATP which present on numerous types of 
cell including stem, blood, glial, neural, bone, endothelial, muscle, renal and skin cells.69 There are previous 
reports that BBG attenuates various types of pain including muscle pain, neuropathic pain, migraine and 
bone cancer pain.18,70-72 In our previous study, BBG attenuated hyperalgesia caused by excessive muscle 
contraction.18 There are several reports that BBG inhibits NLRP3 inflammasome activation in various 
disease models.48,73 Wang S et al reported BBG inhibited NLRP3 inflammasome activation in bone marrow 
derived macrophages on LPS-induced acute lung injury mouse model.48 Similarly, Zhong X et al reported 
inhibition of inhibited NLRP3 inflammasome activation by BBG using graft-versus host disease model mice 
produced by allogeneic hematopoietic stem cell transplantation.73 These reports support our finding that 
BBG inhibited NLRP3 inflammasome activation in the stimulated muscle. 
Z-WEHD-FMK is a caspase-1 inhibitor which inhibits the caspase-1 activity and subsequently 
production of IL-1β.49 There are previous reports that caspase-1 inhibitor attenuated pain.31,74 Li WW et al. 
reported caspase-1 inhibitor attenuated mechanical allodynia in rat model of complex regional pain 
syndrome type I.31 Chen L et al reported caspase-1 inhibitor reduced IL-1β level in rat model of headache 
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induced by intrathecal injection of inflammatory chemicals.74 These reports support our finding that Z-
WEHD-FMK attenuated pain and reduced IL-1β level in the stimulated muscle. 
There are several points to discuss about the results of the caspase-1 activity in drug administration 
tests. First, caspase-1 activity was less decreased compared to IL-1β in treated muscle. This result suggests 
that caspase-1 activity may have a threshold to promote secretion of IL-1β. However, it was difficult to 
determine the threshold value because the caspase-1 activities were presented as ratio in the present study. 
Secondly, in all the results of drug administration tests, caspase-1 activities of treated muscle were increased 
compared with those of non-stimulated muscle. The activation of inflammasomes occur via various type of 
proteins such as NLRP1 and NLRC4 beside NLRP3.27 Recognition of signals by these inflammasome 
proteins result in activation of caspase-1.27 Therefore, it may reflect the caspase-1 activation through other 
inflammasome proteins than NLRP 3, which was caused by electrode puncture or electrical stimulation. 
Our study had the following limitations: (1) the evaluation of inflammasome activation and IL-1β 
levels was performed only in muscle tissues; no additional testing of sensory neurons and the central nervous 
system (CNS) was performed, (2) the evaluation of tissue pH and ATP production was not performed, (3) we 
did not confirm MSU crystal formation using polarizing microscopes, (4) the cut off value of uric acid 
concentration that can induce inflammasome activation was not determined, and (5) an analysis of other 
inflammatory cytokines such as IL-6, TNF-α, and IFN-γ, was not performed. Further studies are expected to 
clarify involvement of sensory neurons and CNS, decrease of tissue pH and increase of ATP production, 
26 
 
MSU crystal formation, the cut off value of uric acid concentration that can induce inflammasome activation, 
and involvement of other inflammatory cytokines in muscle pain. Furthermore, our results can lead to 
research in humans because XO inhibitors, which were used in this study, and anti-IL-1β antibody have 
already been used for human beings safely. 
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6. Conclusions 
IL-1β secretion and NLRP3 inflammasome activation in macrophages due to elevated levels of 
uric acid produced mechanical hyperalgesia through repeated excessive muscle contractions. XO inhibitor 
and anti-IL-1β antibody, having already been used for human beings, may potentially reduce over-exercised 
muscle pain in humans. 
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9. Figure legends 
Figure 1. Position of mouse during electrical stimulation.  
The right hind leg was immobilized with the ankle joint in dorsal flexion so that the triceps surae muscle 
was fully extended to induce isometric contraction (a: overall view, b: enlarged view). 
 
Figure 2. Assessment of pressure pain threshold using Randall-Selitto test  
The Randal-Selitto test employed a cone-shaped plastic tip attached to a scale with a display (a). A 
linearly increasing pressure was applied to the lateral surface of the triceps surae muscle until the elicit 
pain-related behaviors appeared (b). 
 
Figure 3. Change in pressure pain thresholds (PPTs), NLRP3 and IL-1β levels by local 
administration of monosodium urate (MSU)  
Time course of PPT values in the MSU group and saline group (a). The PPTs of the MSU group 
significantly decreased compared to those of the saline group, 1 to 4 days after administration. The 
quantities of NLRP3 (b) and IL-1β (c) in muscle tissues. The protein expression, determined by ELISA, 
increased significantly in MSU groups compared to saline groups. *p < 0.05: significantly different 
from the saline group; #p < 0.05: significantly different from the pre-injection values; The protein 
concentrations for all samples used in the ELISA were equalized to 1.1 mg/ml. 
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Figure 4. Changes in the PPTs and levels of uric acid, NLRP3, caspase-1 and IL-1β in stimulated 
and non-stimulated muscles at 7 days after initiating electrical stimulation. 
Time course of PPT changes (a). The PPTs of stimulated muscles significantly decreased compared with 
that of non-stimulated contralateral muscles, during days 4 to 11 after initiating electrical stimulation; *p 
< 0.05, significantly different from non-stimulated muscle. The quantities of uric acid (b), NLRP3 (c), 
IL-1β (e) and fluorescence intensity of caspase-1 activity (d) in muscle tissues. These levels increased 
significantly in stimulated muscles compared to non-stimulated muscles; the concentrations of NLRP3 
and IL-1β were equalized to 1.1 mg/ml. The concentration of uric acid was shown as nmol/50 μl and the 
fluorescence intensity of caspase-1 activity shown as a ratio to the value of non-stimulated muscles. 
 
Figure 5. The number of macrophages in muscle, with or without electrical stimulation, and the 
effect of clodronate liposome administration 
Immunohistochemical staining of NLRP3 (green), caspase-1 (green), IL-1β (green) and CD68 (red) in 
stimulated and non-stimulated muscles on day 7 are shown (a to r). The number of CD68-positive cells 
(macrophages) in stimulated muscles increased and most of these cells were also positive for NLRP3, 
caspase-1 and IL-1β; scale bar = 50 μm. The number of cells co-positive for IL-1β and CD68 increased 
significantly in stimulated muscles (s). The PPTs increased (t), and levels of NLRP3 (u), caspase-1 
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activity (v) and IL-1β (w) significantly decreased in the clodronate liposome group compared to those in 
the stimulated muscle of the saline group and naïve group. The concentrations of NLRP3 and IL-1β 
were equalized to 1.1 mg/ml. The fluorescence intensity of caspase-1 activity was shown as a ratio with 
the value of non-stimulated muscles in naïve group. 
 
Figure 6. Changes in PPTs and the levels of uric acid, NLRP3, caspase-1 activity and IL-1β 
produced after administration of xanthine oxidase (XO) inhibitors. 
The PPTs increased (a), and levels of uric acid (b), NLRP3 (c), caspase-1 activity (d) and IL-1β (e) 
significantly decreased in the allopurinol group and febuxostat group when compared to the stimulated 
muscles of the saline group and the naïve group. The concentrations of NLRP3 and IL-1β were 
equalized to 1.1 mg/ml and the concentration of uric acid presented as nmol/50 μl. The fluorescence 
intensity of caspase-1 activity was shown as a ratio with the value of non-stimulated muscles in the 
naïve group. 
 
Figure 7. Changes in PPTs and the levels of NLRP3, caspase-1 activity and IL-1β produced after 
administration of brilliant blue G (BBG). 
The PPTs increased (a), and levels of NLRP3 (b), caspase-1 activity (c) and IL-1β (d) significantly 
decreased in the BBG group compared to the stimulated muscles of the saline group and the naïve 
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group. The concentrations of NLRP3 and IL-1β were equalized to 1.1 mg/ml. The fluorescence intensity 
of caspase-1 activity was shown as a ratio to the value of non-stimulated muscles in the naïve group. 
 
Figure 8. Changes in PPTs and the levels of caspase-1 activity and IL-1β produced after 
administration of Z-YVAD-FMK. 
The PPTs increased (a), and levels of caspase-1 activity (b) and IL-1β (c) significantly decreased in the 
Z-YVAD-FMK group compared to the stimulated muscle of saline group and naïve group. The 
concentrations of IL-1β were equalized to 1.1 mg/ml. The fluorescence intensity of caspase-1 activity 
was shown as a ratio with the value of non-stimulated muscles in the naïve group. 
 
Figure 9. Changes in the PPTs in stimulated and non-stimulated muscles of IL-1 knock out mouse 
7 days after initiating electrical stimulation. 
A significant difference was not observed in the PPTs between stimulated and non-stimulated muscles. 
 
Figure 10. Scheme showing the hypothesis of this study and inhibitors at each stage 
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